
Axcella Health AXLA
Quarterly report 2023-Q2
added 08-03-2023
Axcella Health Total Current Liabilities 2011-2026 | AXLA
Annual Total Current Liabilities Axcella Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.1 M | 10.2 M | 7.78 M | 8.36 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.1 M | 7.78 M | 10.1 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
5.75 M | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
NextCure
NXTC
|
10.6 M | $ 10.07 | 1.31 % | $ 28.6 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 19.62 | 2.03 % | $ 917 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Oragenics
OGEN
|
1.8 M | $ 0.65 | 0.69 % | $ 1.4 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Atreca
BCEL
|
16.3 M | - | -11.76 % | $ 5.79 M | ||
|
Omeros Corporation
OMER
|
79.5 M | $ 10.49 | 3.05 % | $ 610 M | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
200 M | - | - | $ 546 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Cara Therapeutics
CARA
|
25.6 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
60.7 M | $ 1.36 | 3.03 % | $ 347 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
20.7 M | $ 8.29 | 1.34 % | $ 110 M | ||
|
CRISPR Therapeutics AG
CRSP
|
149 M | $ 47.67 | 2.67 % | $ 4.29 B | ||
|
Cyclacel Pharmaceuticals
CYCC
|
6.27 M | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
63 M | - | - | $ 3.74 B | ||
|
Processa Pharmaceuticals
PCSA
|
2.24 M | $ 2.32 | -0.23 % | $ 3.04 M | ||
|
Dynavax Technologies Corporation
DVAX
|
78.6 M | - | - | $ 2.02 B | ||
|
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
29.2 M | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Phathom Pharmaceuticals
PHAT
|
132 M | $ 10.39 | 3.28 % | $ 758 M | ||
|
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
BiomX
PHGE
|
6.38 M | $ 4.81 | -3.41 % | $ 7.85 M | ||
|
Phio Pharmaceuticals Corp.
PHIO
|
1.63 M | $ 1.26 | 3.28 % | $ 7.54 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
6.01 M | $ 4.58 | 6.26 % | $ 878 M | ||
|
Homology Medicines
FIXX
|
11.3 M | - | 0.77 % | $ 53.4 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M |